Stereotactic Ablative Radiation Therapy for the Treatment of Oligometastatic Prostate Cancer
Phuoc T. Tran(University of Chicago Medical Center), Mario A. Eisenberger(Johns Hopkins University), Jean L. Wright(University of North Carolina at Chapel Hill), D. Song(Johns Hopkins University), Edward M. Schaeffer(Northwestern University), Ashley E. Ross(St. Jude Children's Research Hospital), Curtiland Deville(Johns Hopkins University), Diane K. Reyes(Johns Hopkins University), Noura Radwan(Johns Hopkins University), Michael A. Carducci(Sidney Kimmel Comprehensive Cancer Center), Kenneth J. Pienta(Johns Hopkins University), Theodore L. DeWeese(Johns Hopkins University)
International Journal of Radiation Oncology*Biology*Physics
October 1, 2016
Cited by 2
Related Papers
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
|Journal of Clinical Oncology|2018|1.1k